Articles related to PSYCHEDELICS

The FDA’s guidance on psychedelic medicine is a landmark in mental health treatment. With the potential to treat PTSD, addiction, and treatment-resistant depression, psychedelics could heighten the field. However, the guidance also highlights the need for rigorous study of these substances, particularly regarding their subjective effects and the role of psychological support.

The use of psychedelics in treating substance use disorder (SUD) is showing promise. A 2012 meta-analysis suggests a favorable probability of reduced alcohol use upon administration of LSD in a controlled context.

A Phase 2B study found that a 25mg dose of psilocybin, combined with psychotherapy, produced a significant drop in patients’ scores on the Montgomery Asberg Depression Rating Scale (MADRS) after 12 weeks. This finding underscores the potential of psilocybin-assisted therapy as a promising treatment for depression.

Discover how MDMA-assisted therapy is setting new benchmarks in PTSD treatment, offering clinically meaningful improvements and a strong safety profile.

Discover the advancements in MDD pharmacotherapy that promise to expand treatment options and address unmet needs.

The newly released guidelines for psychedelic-assisted therapy by APPA and BrainFutures provide a comprehensive framework for mental health professionals. Explore the guidelines to understand the benchmarks for safety, ethics, and best practices in this emerging field.